Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Harnessing immunogenic cell death (ICD)—an immunostimulatory form of cancer cell death in the tumor microenvironment—to help activate a patient’s immunity and trigger a tumor-specific immune ...

mRNA therapeutics hold promise as the next generation of drugs for tissue restoration in regenerative medicine. The ...

Researchers evaluated the immunogenicity of hepatitis A virus vaccination as well as responses in patients with HIV and those on immunosuppressive therapy.

The team, led by Martin McIntosh, Ph.D., head of the Computational Biology Program at Fred Hutch, is using high-throughput technology and emerging public data resources to help identify hundreds of ...

Therefore, it is desirable to perform more extensive histocompatibility testing for the most immunogenic organs, but the length of cold ischemia time an organ will tolerate limits the extent of ...